NASDAQ:BMRN - BioMarin Pharmaceutical Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $89.49 +0.94 (+1.06 %) (As of 03/26/2019 03:15 PM ET)Previous Close$88.55Today's Range$88.61 - $89.7252-Week Range$75.81 - $106.74Volume667,889 shsAverage Volume983,030 shsMarket Capitalization$15.96 billionP/E Ratio-271.18Dividend YieldN/ABeta1.53 ProfileDiscussionAnalyst RatingsChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email BioMarin Pharmaceutical, Inc., a biotechnology company, develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Aldurazyme that is used for the treatment of patients with mucopolysaccharidosis I, a genetic disease; Brineura for the treatment of late infantile neuronal ceroid lipofuscinosis type 2, a form of Batten disease; and Firdapse for Lambert Eaton Myasthenic Syndrome. The company's commercial products also comprise Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria, an inherited metabolic disease; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with mucopolysaccharidosis VI; and Vimizim, an enzyme replacement therapy for the treatment of MPS IV A, a lysosomal storage disorder. Its clinical and pre-clinical product pipeline includes pegvaliase, an enzyme substitution therapy for the treatment of phenylketonuria; vosoritide, a peptide therapeutic for the treatment of achondroplasia, a form of disproportionate short stature in humans; valoctocogene roxaparvovec, an AAV5 vector and factor VIII gene therapy drug development candidate for the treatment of severe hemophilia A; BMN 250, an investigational enzyme replacement therapy for the treatment of Sanfilippo Syndrome Type B or mucopolysaccharidosis type IIIB; and BMN 290, a selective chromatin modulation therapy for the treatment of Friedreich's ataxia. The company serves specialty pharmacies; and end-users, such as hospitals and foreign government agencies, as well as distributors and pharmaceutical wholesalers in the United States, Europe, Latin America, and internationally. BioMarin Pharmaceutical Inc. has collaboration agreements with Sarepta Therapeutics and Genzyme Corporation; and a license agreement with Asubio Pharma Co., Ltd. The company was founded in 1996 and is headquartered in San Rafael, California. Receive BMRN News and Ratings via Email Sign-up to receive the latest news and ratings for BMRN and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryBiotechnology SectorMedical Current SymbolNASDAQ:BMRN Previous Symbol CUSIP09061G10 CIK1048477 Webwww.bmrn.com Phone415-506-6700Debt Debt-to-Equity Ratio0.28 Current Ratio3.93 Quick Ratio2.92Price-To-Earnings Trailing P/E Ratio-271.18 Forward P/E Ratio4,474.50 P/E GrowthN/A Sales & Book Value Annual Sales$1.49 billion Price / Sales10.70 Cash Flow$0.2176 per share Price / Cash Flow411.30 Book Value$16.67 per share Price / Book5.37Profitability EPS (Most Recent Fiscal Year)($0.33) Net Income$-77,210,000.00 Net Margins-5.18% Return on Equity-2.79% Return on Assets-1.76%Miscellaneous Employees2,849 Outstanding Shares178,370,000Market Cap$15.96 billion Next Earnings Date4/24/2019 (Estimated) OptionableOptionable BioMarin Pharmaceutical (NASDAQ:BMRN) Frequently Asked Questions What is BioMarin Pharmaceutical's stock symbol? BioMarin Pharmaceutical trades on the NASDAQ under the ticker symbol "BMRN." How were BioMarin Pharmaceutical's earnings last quarter? BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) issued its quarterly earnings results on Thursday, February, 21st. The biotechnology company reported ($0.02) earnings per share for the quarter, topping the Zacks' consensus estimate of ($0.09) by $0.07. The biotechnology company earned $353 million during the quarter, compared to analysts' expectations of $377.35 million. BioMarin Pharmaceutical had a negative net margin of 5.18% and a negative return on equity of 2.79%. BioMarin Pharmaceutical's quarterly revenue was down 1.4% compared to the same quarter last year. During the same quarter in the prior year, the business earned $0.03 EPS. View BioMarin Pharmaceutical's Earnings History. When is BioMarin Pharmaceutical's next earnings date? BioMarin Pharmaceutical is scheduled to release their next quarterly earnings announcement on Wednesday, April 24th 2019. View Earnings Estimates for BioMarin Pharmaceutical. What price target have analysts set for BMRN? 18 Wall Street analysts have issued 1 year price objectives for BioMarin Pharmaceutical's shares. Their predictions range from $81.00 to $145.00. On average, they expect BioMarin Pharmaceutical's stock price to reach $114.2107 in the next year. This suggests a possible upside of 27.6% from the stock's current price. View Analyst Price Targets for BioMarin Pharmaceutical. What is the consensus analysts' recommendation for BioMarin Pharmaceutical? 18 Wall Street analysts have issued "buy," "hold," and "sell" ratings for BioMarin Pharmaceutical in the last year. There are currently 5 hold ratings and 13 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for BioMarin Pharmaceutical. What are Wall Street analysts saying about BioMarin Pharmaceutical stock? Here are some recent quotes from research analysts about BioMarin Pharmaceutical stock: 1. Cantor Fitzgerald analysts commented, ". We reiterate our OW and increase our TP to $131 from $126. We update our model to reflect Friday’s positive CHMP opinion on Palynziq: we increased our probability of EU sales from 75% to 100%. Management sounded upbeat about the EU review process on the recent earnings call and at conferences, so we don’t think the CHMP news was a major surprise to investors. We think this approval is supportive of base business revenue growth, and we model worldwide Palynziq sales of $900M ($200M of which from EU) for 2025." (3/4/2019) 2. According to Zacks Investment Research, "BioMarin missed estimates for both earnings and sales in Q4. BioMarin’s key orphan disease drugs – Vimizim and Kuvan – continue to do well, on the back of strong demand trends. Its newest product, Palynziq’s U.S. launch is progressing well. Its rare disease pipeline is also progressing well. Growing pipeline focus toward gene therapy agents is encouraging However, BioMarin has suffered a few regulatory setbacks related to its pipeline candidates in the past. Further development setbacks can have a negative impact on the stock. Moreover, Naglazyme and Vimzin revenues vary on a quarterly basis, primarily owing to infrequent ordering patterns from some countries, mainly Brazil. Meanwhile, BioMarin is facing a generic threat for Kuvan in 2020. The earlier-than-expected entry of generics will be a huge blow for the company." (3/1/2019) Has BioMarin Pharmaceutical been receiving favorable news coverage? News headlines about BMRN stock have trended somewhat positive on Tuesday, InfoTrie Sentiment Analysis reports. InfoTrie identifies negative and positive media coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. BioMarin Pharmaceutical earned a news sentiment score of 1.7 on InfoTrie's scale. They also gave news articles about the biotechnology company a news buzz of 6.0 out of 10, indicating that recent media coverage is somewhat likely to have an impact on the stock's share price in the near term. Who are some of BioMarin Pharmaceutical's key competitors? Some companies that are related to BioMarin Pharmaceutical include Celgene (CELG), Bayer (BAYRY), Shire (SHPG), Allergan (AGN), Zoetis (ZTS), Vertex Pharmaceuticals (VRTX), Regeneron Pharmaceuticals (REGN), Takeda Pharmaceutical (TAK), Takeda Pharmaceutical (TKPYY), ASTELLAS PHARMA/ADR (ALPMY), Alexion Pharmaceuticals (ALXN), Shiseido (SSDOY), UCB (UCBJF), Teva Pharmaceutical Industries (TEVA) and Ono Pharmaceutical (OPHLF). What other stocks do shareholders of BioMarin Pharmaceutical own? Based on aggregate information from My MarketBeat watchlists, some companies that other BioMarin Pharmaceutical investors own include Gilead Sciences (GILD), Celgene (CELG), Netflix (NFLX), Allergan (AGN), Incyte (INCY), Amgen (AMGN), Biogen (BIIB), Micron Technology (MU), Alibaba Group (BABA) and NVIDIA (NVDA). Who are BioMarin Pharmaceutical's key executives? BioMarin Pharmaceutical's management team includes the folowing people: Mr. Jean-Jacques Bienaimé MBA, Chairman & CEO (Age 66)Mr. Daniel K. Spiegelman, Exec. VP & CFO (Age 60)Dr. Robert A. Baffi, Exec. VP of Technical Operations (Age 64)Mr. Jeffrey Robert Ajer, Exec. VP & Chief Commercial Officer (Age 57)Dr. Henry J. Fuchs, Pres of Worldwide R&D (Age 61) Who are BioMarin Pharmaceutical's major shareholders? BioMarin Pharmaceutical's stock is owned by a number of of retail and institutional investors. Top institutional shareholders include Jennison Associates LLC (6.51%), Geode Capital Management LLC (0.92%), venBio Select Advisor LLC (0.76%), Frontier Capital Management Co. LLC (0.76%), Norges Bank (0.67%) and Northern Trust Corp (0.66%). Company insiders that own BioMarin Pharmaceutical stock include Alan Lewis, Brian Mueller, Daniel K Spiegelman, Elaine J Heron, George Eric Davis, Henry J Fuchs, Jean Jacques Bienaime, Jeffrey Robert Ajer, Richard A Meier, Robert Baffi and V Bryan Lawlis. View Institutional Ownership Trends for BioMarin Pharmaceutical. Which institutional investors are selling BioMarin Pharmaceutical stock? BMRN stock was sold by a variety of institutional investors in the last quarter, including GAM Holding AG, Orbimed Advisors LLC, Mizuho Securities USA LLC, Manning & Napier Group LLC, Millennium Management LLC, First Trust Advisors LP, Sectoral Asset Management Inc and Rhenman & Partners Asset Management AB. Company insiders that have sold BioMarin Pharmaceutical company stock in the last year include Alan Lewis, Brian Mueller, Daniel K Spiegelman, Elaine J Heron, George Eric Davis, Henry J Fuchs, Jean Jacques Bienaime, Jeffrey Robert Ajer, Richard A Meier, Robert Baffi and V Bryan Lawlis. View Insider Buying and Selling for BioMarin Pharmaceutical. Which institutional investors are buying BioMarin Pharmaceutical stock? BMRN stock was purchased by a variety of institutional investors in the last quarter, including Norges Bank, Jennison Associates LLC, Thrivent Financial for Lutherans, Sofinnova Investments Inc., Mackenzie Financial Corp, Massachusetts Financial Services Co. MA, Geode Capital Management LLC and Northern Trust Corp. View Insider Buying and Selling for BioMarin Pharmaceutical. How do I buy shares of BioMarin Pharmaceutical? Shares of BMRN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is BioMarin Pharmaceutical's stock price today? One share of BMRN stock can currently be purchased for approximately $89.49. How big of a company is BioMarin Pharmaceutical? BioMarin Pharmaceutical has a market capitalization of $15.96 billion and generates $1.49 billion in revenue each year. The biotechnology company earns $-77,210,000.00 in net income (profit) each year or ($0.33) on an earnings per share basis. BioMarin Pharmaceutical employs 2,849 workers across the globe. What is BioMarin Pharmaceutical's official website? The official website for BioMarin Pharmaceutical is http://www.bmrn.com. How can I contact BioMarin Pharmaceutical? BioMarin Pharmaceutical's mailing address is 770 Lindaro Street, San Rafael CA, 94901. The biotechnology company can be reached via phone at 415-506-6700 or via email at [email protected] MarketBeat Community Rating for BioMarin Pharmaceutical (NASDAQ BMRN)Community Ranking: 3.3 out of 5 ( )Outperform Votes: 1,151 (Vote Outperform)Underperform Votes: 610 (Vote Underperform)Total Votes: 1,761MarketBeat's community ratings are surveys of what our community members think about BioMarin Pharmaceutical and other stocks. Vote "Outperform" if you believe BMRN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe BMRN will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 3/26/2019 by MarketBeat.com StaffFeatured Article: What is intrinsic value?